COL6A3

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Retrieved on: 
Tuesday, March 21, 2023

In October 2022, Immatics provided an interim update on the ongoing IMA203 TCR-T monotherapy trial covering data from 27 patients in the completed Phase 1a dose escalation and the first 5 patients in the Phase 1b dose expansion trial.

Key Points: 
  • In October 2022, Immatics provided an interim update on the ongoing IMA203 TCR-T monotherapy trial covering data from 27 patients in the completed Phase 1a dose escalation and the first 5 patients in the Phase 1b dose expansion trial.
  • This allows Immatics to shorten the turnaround time and to provide the cell therapy product candidate to patients faster.
  • In October 2022, GSK provided Immatics with notice of its decision to terminate their collaboration.
  • Immatics successfully completed an underwritten public offering in October 2022, raising approximately $110 million before deducting underwriting discount and offering expenses.

Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME

Retrieved on: 
Tuesday, November 9, 2021

ACTengine IMA204 is a potential first-in-class TCR-T directed against COL6A3 exon 6, a novel tumor stroma target highly expressed in several solid cancers.

Key Points: 
  • ACTengine IMA204 is a potential first-in-class TCR-T directed against COL6A3 exon 6, a novel tumor stroma target highly expressed in several solid cancers.
  • Submission of the IND application for IMA204 is now expected in 2022 to allow accelerated initiation of the multiple ACTengine IMA203 Ph1b cohorts.
  • Immatics PRAME peptide demonstrates a high copy number per tumor cell and is homogenously and specifically expressed in tumor tissue.
  • ACTengine IMA203 is currently being evaluated in an ongoing Phase 1a dose escalation cohort utilizing a 3+3 design with four increasing IMA203 dose levels to determine the Recommended Phase 2 Dose (RP2D).